Pulmonary arterial hypertension: Bridging the present to the future

European Respiratory Review

Volumn 21, Issue 126, 2012, Pages 267-270

  Humbert, Marc ^a,b   Souza, Rogerio ^c   Galie, Nazzareno ^d   McLaughlin, Vallerie ^e   Simonneau, Gérald ^a,b   Rubine, Lewis ^f  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Universite Paris Sud   (France)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; IMATINIB; MACITENTAN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TERGURIDE; TREPROSTINIL;

CARDIOVASCULAR SURGERY; CLINICAL TRIAL (TOPIC); CONGENITAL HEART DISEASE; CONTINUING EDUCATION; DIAGNOSTIC ACCURACY; DOPPLER ECHOCARDIOGRAPHY; DOWN SYNDROME; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EDITORIAL; EXERCISE; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; IRELAND; LUNG VASCULAR RESISTANCE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDICAL SOCIETY; PATIENT CARE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; CONGRESSES AS TOPIC; DELAYED DIAGNOSIS; DRUGS, INVESTIGATIONAL; EARLY DIAGNOSIS; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; PERIODICALS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84870736179     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00005312     Document Type: Editorial

References (39)

1. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
2. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
3. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
4. Humbert M, Sitbon O, Yai{dotless}̈ci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
5. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
6. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39: 945-955.
7. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124: 1973-1981.
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
9. O'Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011; 8: 526-538.
10. Galie' N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
11. Galie' N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
12. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
13. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
14. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.
15. Vachiéry J-L, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 313-320.
16. Galie' N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
17. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: howREVEAL differs fromhistoric and non-US Contemporary Registries. Chest 2011; 139: 128-137.
18. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.
19. Humbert M, Coghlan JG, Khanna D. Early detection and management of pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 306-312.
20. D'Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev 2012; 21: 328-337.
21. Daniels CJ. Adult congenital heart disease and pulmonary hypertension: management of a complex case. Eur Respir Rev 2012; 21: 362-364.
22. Haworth SG. Pulmonary hypertension in the young. Heart 2002; 88: 658-664.
23. Baumgartner H, Bonhoeffer P, De Groot NM, et al. SC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31: 2915-2957.
24. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol 2008; 52: e143-e263.
25. Galie' N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
26. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
27. Barst RJ, Miller DP, Beery F, et al. Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry. Am J Respir Crit Care Med 2011; 183: A5941.
28. Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49: 490-500.
29. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
30. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-596.
31. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
32. Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012; 21: 321-327.
33. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327: 736-745.
34. Iglarz M, Landskroner K, Rey M, et al. Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 183: A6445.
35. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010; 11: 1066-1073.
36. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792.
37. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
38. Guazzi M, Galie' N. Pulmonary hypertension in left heart disease. Eur Respir Rev 2012; 21: 338-346.
39. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009; 136: 37-43.